Clemedi
Schlieren
About Clemedi
Clemedi develops in vitro diagnostic tests for infectious diseases, by uniting two novel technologies – Next-generation Sequencing and Machine learning. They will contribute to limiting deaths caused by antibiotic resistant bacteria, projected to reach 10 million annually in 2050! Our diagnostic tests support doctors’ decision-making by enabling him or her to give a timely and personalized antibiotic therapy. Ultimately, patients suffering from infectious diseases will benefit with their product.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $30.7K
- Last round: Non-Equity Assistance (May 2019)
- Website: clemedi.com
- Phone: +41 77 98 040 61
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/clemedi-2239901 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.